Peptides
Peptide database
By goal Fat lossMuscle growthHealing and recoveryLongevityCognition and moodSkin and hairSexual healthImmunity and gut
Guides All guides What are peptides?Legal status in the USPharma vs compounded vs researchHow to read a COAReconstitution and storageMembersThe complete GLP-1 guideSide effects and red flagsHow to read peptide research
Tools All tools Reconstitution calculatorMembersMeasurement converterMembersHalf-life visualizerCompare peptidesPeptide finderGLP-1 titration viewerMembers
Topics
Sleep & Recovery Energy & Vitality Focus & Mind Strength & Performance Longevity & Aging Beauty & Skin Hormones & Metabolism Gut & Immunity
Resources
Peptide Database Peptide Tools Peptide Guides Lab Reader Compound Database Wearables & Devices Calculators Glossary
Newsletter Members: log in or create a free account Join free
Peptide guide

Side effects and red flags

Most peptide side effects are mild and predictable: nausea on GLP-1 drugs, flushing on PT-141, a red bump where the needle went in. A short list is not. Trouble breathing, chest pain, severe stomach pain, spreading redness with fever, or an erection lasting hours means stop and get care. Use the checker below to sort one from the other.

Call 911

Get emergency care for any of these

Trouble breathing, or swelling of lips, tongue or throatAnaphylaxis can follow any injected peptide.
Chest pain or faintingWhatever you took, this needs an emergency assessment.
Sudden vision loss in one eyeA very rare semaglutide effect; any cause needs same-hour care.
An erection lasting more than 4 hoursReported with melanotan II. Tissue damage starts within hours.
Confusion, seizure or passing outLow blood sugar or low sodium are possible causes.
Thoughts of harming yourselfCall or text 988, or 911 if you are in danger.
Symptom checker

Match what you feel to how fast to act

Pick what you are taking, then the symptom. The urgency comes from the symptom alone, so a serious one routes to care whatever the product.

If you think this is an emergency, call 911. This tool sorts symptoms into how fast to act. It cannot diagnose you.
1. What are you taking?
2. What are you noticing?
Breathing and heart
Stomach and gut
Injection site
Skin
Hormones and fluid
Seek care today

Stop the product and get seen today

Redness that keeps spreading, warmth, pus, red streaks or fever

These are signs of a skin infection or abscess. Cellulitis can spread into the blood. Non-sterile vials, reused needles and preservative-free water entered more than once are the usual causes. Get seen today; mark the edge of the redness with a pen so the clinician can see if it is growing.

Linked to:GLP-1 drugsGH secretagoguesPT-141, melanotanBPC-157, TB-500, GHK-CuhCG, oxytocinIGF-1 LR3

Source: MedlinePlus: Cellulitis; CDC Injection Safety

Bring the vial or pen with you if you seek care. For a research-labeled product, the label may not match what is inside, and the clinician needs to know that.
Injection sites

A normal reaction vs an infection

Left: a small, sharp-edged red bump. Right: spreading redness with a pen line it has crossed, a pus center and a red streak. EXPECTED pen line from yesterday GET SEEN TODAY
Usually fine
  • Small, with a clear edge
  • Stays the same size or shrinks
  • Itchy or tender, not hot
  • Gone within a few days
Signs of infection
  • Redness that spreads past a pen line
  • Warm or hot to the touch, more painful each day
  • Pus, a soft lump or red streaks
  • Fever or chills

Infections come from what got into the vial or onto the needle: reused needles, preservative-free water entered more than once, or a non-sterile product. The reconstitution guideMembers covers the handling habits that prevent them.

By peptide class

Expected effects and stop signs, class by class

GLP-1 and incretin drugsSemaglutide, tirzepatide, retatrutide
Common, usually settles
  • Nausea: 44% vs 16% on placebo (Wegovy label)
  • Diarrhea, vomiting, constipation, mostly during dose increases
  • Burning or tingling skin at higher doses
Stop and call
  • Severe stomach pain that does not let up, possibly to the back (pancreatitis)
  • Pain under the right ribs, fever, yellow eyes (gallbladder)
  • Unable to keep fluids down (kidney injury risk)
  • Racing heart at rest that does not settle

Approved drugs with large trials, so these rates are well measured.

SemaglutideTirzepatideRetatrutide
Growth hormone secretagogues and GHRH analogsIpamorelin, CJC-1295, MK-677, tesamorelin, sermorelin
Common, usually settles
  • Injection-site redness: about 70% in a CJC-1295 trial, 25% on tesamorelin
  • Flushing and headache within minutes (CJC-1295)
  • Hunger (MK-677), water retention, joint aches
Stop and call
  • Swelling with shortness of breath (heart failure was seen with MK-677 in frail patients)
  • Thirst and frequent urination (raised blood sugar)
  • Numb or tingling hands that persist (carpal tunnel)

Only tesamorelin is FDA-approved. The others have small human studies that measured hormone levels, not long-term safety.

TesamorelinCJC-1295MK-677 (Ibutamoren)Ipamorelin
MelanocortinsPT-141 (bremelanotide), melanotan I and II
Common, usually settles
  • Nausea: 40% in PT-141 trials, usually better by the second dose
  • Flushing (about 20%) and headache (about 11%)
  • Blood pressure up for 2 to 4 hours after PT-141
Stop and call
  • Erection longer than 4 hours (melanotan II case reports)
  • New, darkening or changing moles
  • Dark patches on face or gums
  • Dark urine with severe muscle pain

PT-141 is FDA-approved as Vyleesi. Melanotan II is not approved anywhere, and its serious harms come from case reports in people using online products.

PT-141 (Bremelanotide)Melanotan-2Melanotan-1 (afamelanotide)
Tissue-repair research peptidesBPC-157, TB-500, GHK-Cu injections
Common, usually settles
  • No characterized profile. Fewer than 100 people have received BPC-157 in published studies; nobody has received TB-500
Stop and call
  • Spreading redness, warmth, pus or fever at the site
  • Hives or swelling after a dose
  • Skin or gum darkening (one FDA report with a BPC-157 plus TB-500 blend)

The main risks here are unknowns: FDA flagged possible immune reactions from impurities and clumped peptide in its 2026 reviews.

BPC-157TB-500GHK-Cu
Reproductive hormoneshCG, oxytocin, kisspeptin
Common, usually settles
  • Injection-site pain, headache, fatigue (hCG label)
  • Fluid retention from raised androgens (hCG)
Stop and call
  • Breast tissue growth in men (hCG)
  • Sudden abdominal swelling or shortness of breath during fertility use (ovarian hyperstimulation)
  • Confusion or seizure with oxytocin (low sodium)

hCG and oxytocin are approved drugs with long label histories.

hCG (Human Chorionic Gonadotropin)OxytocinKisspeptin-10
Growth factorsIGF-1 LR3, PEG-MGF
Common, usually settles
  • None established. No human safety study of IGF-1 LR3 exists
Stop and call
  • Shaky, sweaty, confused (low blood sugar; the native IGF-1 label warns of seizures)
  • Severe headache with vision changes (raised skull pressure on the native IGF-1 label)

Everything known comes from native IGF-1 (mecasermin) and lab work. LR3 was designed to stay active longer.

IGF-1 LR3PEG-MGF
Not the peptide itself

Risks that come from the product, not the molecule

Approved drugs are made and tested under federal manufacturing rules. Research-labeled vials are not, which adds risks that have nothing to do with what the peptide does in the body.

ContaminationBacteria and bacterial toxins (endotoxin) from non-sterile manufacturing cause fever, chills and site infections. Approved drugs are tested for both; research-labeled vials are not required to be.
Wrong contentA vial can hold less, more, or something other than the label says. FDA found a seized IGF-1 product that was a lab-reagent form never meant for injection.
Clumped peptideAggregated chains and synthesis by-products can provoke the immune system. FDA cited this risk for BPC-157, TB-500, CJC-1295 and others.
Dosing errorsConfusing syringe units with milligrams caused 5- to 20-fold overdoses of compounded semaglutide in reports FDA collected in 2024.

What a certificate of analysis can and cannot rule out is covered in how to read a COA.

After the fact

Report it, even for unapproved products

FDA MedWatch Patients can report any reaction to any drug, including compounded and research-labeled products. These reports are how FDA found the semaglutide dosing errors. Open MedWatch
Poison Control For a suspected overdose or a wrong product, US Poison Control answers 24 hours a day and can tell you whether you need care. 1-800-222-1222
988 Lifeline Call or text 988 in the US for thoughts of self-harm, whatever the cause. Call 988
Keep going

Related guides and tools

Pharma vs compounded vs researchThree supply chains, three levels of quality control.How to read a COAPurity, mass spec, endotoxin and what a certificate cannot tell you.Reconstitution and storageMembersBacteriostatic water, fridge vs freezer, and how fast peptides degrade.The complete GLP-1 guideSemaglutide, tirzepatide and what comes next, trial by trial. Reconstitution calculatorMembersWorks out the concentration of a mixed vial, step by step.Measurement converterMembersReads a volume mark as a volume and an amount, with the math shown.Compare peptidesTwo or three peptides side by side on evidence and status.
The Staate peptide brief

Safety signals and label changes, when they happen

New FDA warnings, label updates and safety findings on peptides, checked against the source. One email a week.
Frequently asked questions
What are the warning signs of pancreatitis on a GLP-1 drug?
The Wegovy label describes persistent or severe abdominal pain, sometimes spreading to the back, with or without vomiting. If that happens, stop the drug and get seen promptly, in an emergency department if the pain is severe. Pancreatitis is rare but was among the harms FDA listed in people who overdosed on compounded semaglutide.
How do I tell a normal injection-site reaction from an infection?
A normal reaction is a small red bump, itch or bruise that stays the same size and fades within a few days. An infection keeps spreading, feels warm or hot, gets more painful, may drain pus, can show red streaks running from the site, and may come with fever. Mark the edge of the redness with a pen: if it grows past the line, get seen the same day.
Are side effects from research peptides like BPC-157 known?
Mostly not. Fewer than 100 people have received BPC-157 in published human studies, and no published study has given TB-500 to a person. FDA has flagged immune reactions to impurities and clumped peptide as a concern for both. The absence of reported side effects reflects the absence of studies, not evidence of safety.
What should I do if I have a serious reaction to a peptide?
Get care first: call 911 for breathing trouble, chest pain, fainting, confusion or swelling of the face or throat. Bring the vial or pen. Afterwards, report it to FDA MedWatch, which accepts reports from patients about any drug, including compounded and unapproved products. US Poison Control is reachable at 1-800-222-1222.
Is nausea on semaglutide or tirzepatide a reason to stop?
Usually not. It is the most common side effect and is worst during dose increases. It becomes a problem when you cannot keep fluids down, because dehydration caused most of the kidney injury cases on the label, or when it comes with severe stomach pain. Prescribers can slow the dose increase.
Does melanotan cause skin cancer?
It has not been proven to, but there are at least four case reports of melanoma in people using melanotan II, plus many reports of new or darkening moles. Users often also tan heavily and have many moles, which makes cause hard to separate. Any changing mole should be checked by a dermatologist.
Sources
  1. FDA prescribing information: Wegovy (DailyMed), Warnings and Precautions 5.1 to 5.11 and Table 3.
  2. FDA. Vyleesi (bremelanotide injection) prescribing information (2019).
  3. FDA (2025). EGRIFTA WR (tesamorelin for injection) prescribing information.
  4. Increlex (mecasermin) injection prescribing information, DailyMed.
  5. Novarel (chorionic gonadotropin) prescribing information, DailyMed.
  6. FDA (2024). Briefing document: CJC-1295-related bulk drug substances. Pharmacy Compounding Advisory Committee.
  7. FDA (2024). Briefing document: Ibutamoren mesylate (MK-677). Pharmacy Compounding Advisory Committee.
  8. FDA (2026). BPC-157-related bulk drug substances: briefing document. Pharmacy Compounding Advisory Committee.
  9. FDA (2026). TB-500-related bulk drug substances: briefing document. Pharmacy Compounding Advisory Committee.
  10. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.
  11. FDA (2024). Dosing errors associated with compounded injectable semaglutide products.
  12. European Medicines Agency (2025). PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines.
  13. Hjuler KF, Lorentzen HF (2014). Melanoma associated with the use of melanotan-II. Dermatology.
  14. Nelson ME et al. (2012). Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol.
  15. Mallory CW et al. (2021). Melanotan Tanning Injection: A Rare Cause of Priapism. Sex Med.
  16. MedlinePlus. Anaphylaxis.
  17. MedlinePlus. Cellulitis.
  18. MedlinePlus. Low blood sugar.
  19. U.S. CDC. Injection Safety: clinical safety practices.
  20. U.S. FDA. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.
  21. 988 Suicide and Crisis Lifeline.

This is educational information, not medical advice. Talk to a qualified healthcare professional before changing your treatment, medication, or supplement routine, especially if you are pregnant, nursing, or managing a health condition.